Tricard is commonly used in conditions where symptoms may intensify temporarily, providing supportive symptom management when standard treatments are insufficient. This primary use is relevant for easing symptoms related to physical discomfort and noticeable physiological strain that manifest as recurrent chest pain during exertion. Its application is relevant in clinical settings associated with myocardial ischemia and the resulting symptomatic patterns.

The core therapeutic benefit is focused on providing support that helps ease the overall symptom burden associated with chronic angina. It assists in managing the severity and frequency of these recurrent or episodic manifestations. By assisting the heart during periods of heightened physiological activity, Tricard contributes to improved comfort and supports the patient in maintaining functional stability when symptoms interfere with routine activities. This supportive role may assist with reducing the reliance on acute, fast-acting relief medications.

“The treatment contributes to improved comfort and helps patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability.”

---

Quick Fact: Support for Symptoms Related to Exertional Discomfort Tricard supports general well-being during symptomatic phases, which may assist with maintaining functional stability when patients experience physical effort.

The use of Tricard (Trimetazidine Dihydrochloride) is strictly defined by regulatory eligibility criteria, focusing only on specific adult populations and excluding several patient groups based on underlying conditions or age.

Who Must Not Use Tricard (Contraindications)

Official labeling defines absolute non-eligibility for the following groups:

• Movement Disorders: Patients diagnosed with Parkinson's disease, or those experiencing existing Parkinsonian symptoms (such as tremor, rigidity, or walking instability).
• Severe Renal Impairment: Individuals with severely diminished kidney function, specifically a creatinine clearance (CLcr) below 30 mL/min.
• Hypersensitivity: Patients with known allergy or hypersensitivity to the active ingredient or any component of the tablet.

Restricted and Non-Recommended Use

The medicine is established for use only in adults for stable symptomatic conditions. Use is not recommended in several populations:

Population Group	Regulatory Status
Children and Adolescents (under 18)	Use is not recommended as safety and efficacy have not been established.
Moderate Renal Impairment	Use is not recommended, often requiring careful consideration due to reduced drug clearance.
Older Adults (over 75 years)	Use requires special caution due to potential age-related decline in kidney function.
Pregnancy and Breastfeeding	Use is not recommended due to insufficient data regarding risk.

Tricard Interactions with other medicines and products

The official regulatory documents for Trimetazidine Dihydrochloride define a profile characterized by the absence of conventional drug–drug interactions. No specific medicinal products or product categories are identified as requiring restriction or caution due to a confirmed interaction with this medicine.

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	None officially identified or reported in regulatory documents.
Timing-based interaction rules (if applicable)	None required for separation from meals or other medicines; the drug's pharmacokinetic profile is documented as not being influenced by meals.
Population-specific interaction notes (if applicable)	Increased systemic exposure is expected in patients with Moderate renal impairment (creatinine clearance 30-60 mL/min) and in Elderly patients (older than 75 years old).

The official labeling explicitly confirms that no drug interactions have been identified, suggesting no known alterations in the effects or concentration of co-administered substances. This high degree of interaction neutrality extends to foodstuffs, as the medicine's systemic exposure is not affected by meals. The primary interaction-related consideration is pharmacokinetic: a reduction in renal clearance in specific patient populations—specifically the elderly and those with moderate kidney impairment—results in an officially noted increase in systemic drug exposure. This finding is the basis for required constraints related to patient condition, rather than the combination of substances. The overall interaction structure confirms that no interaction-based prohibitions or mandatory timing rules are currently documented in the medicine's official labeling.

Fuel Preference Shift in Heart Cells

Tricard's mechanism of action involves acting as a partial inhibitor of the enzyme Mitochondrial Long-Chain 3-Ketoacyl-CoA Thiolase (3-KAT) within heart muscle cells. This molecular interaction modifies myocardial energy metabolism, initiating a metabolic shift that promotes the heart's utilization of the oxygen-efficient fuel, glucose, over fatty acids.

---

Modulating Oxygen Utilization Efficiency

The alteration in the heart's primary energy substrate modifies the myocardial oxygen utilization efficiency, resulting in a change in the ratio of oxygen consumption to energy (ATP) produced. This adjustment contributes to the preservation of the cell's internal energy balance and functional integrity during conditions of metabolic stress.

---

Modifying Functional Capacity

By adjusting cellular energy efficiency and preserving the internal stability of heart muscle cells, the mechanism contributes to a modification of the heart's functional capacity. This process results in a physiological adjustment of myocardial capacity.

How Tricard is Used

Tricard, containing the active ingredient Trimetazidine Dihydrochloride, is administered via the oral route as a 35 mg Modified-Release (MR) tablet. Usage involves a standardized daily regimen and specific administration conditions.

---

Standard Dosage and Frequency

The standard adult dosage is one 35 mg tablet twice daily. The doses are taken once in the morning and once in the evening, establishing a 70 mg total daily dose. This twice-daily frequency is designed to ensure consistent release and systemic levels of the medicine over a 24-hour period.

---

Administration Context and Course Assessment

For proper administration, the Modified-Release tablet must be taken during meals. The tablet must be swallowed whole and should not be crushed or chewed, as this compromises the modified-release properties of the formulation. If a scheduled dose is missed, the dose should not be doubled to compensate; treatment should be resumed normally with the next scheduled dose.

Treatment benefit is subject to assessment after three months of consistent use; if no appropriate response is determined at this point, continued use should be re-evaluated.

---

Population-Specific Use

Dosing is modified for specific populations. For individuals with moderate renal impairment (creatinine clearance 30-60 mL/min), the dose is reduced to one 35 mg tablet once daily in the morning. This adjustment is also applicable to older adults who may experience age-related decline in kidney function. The product is not recommended for use in pediatric patients (below 18 years of age).

Research Evidence / Overview of Studies for Tricard

Evidence for the Symptomatic Treatment of Chronic Stable Angina Pectoris

Research has focused on Tricard's role when studied alongside standard anti-anginal medications for the symptoms of chronic stable angina pectoris, which is chest pain caused by the heart muscle not receiving enough oxygen. The main body of research consists of short-term Randomized Controlled Trials (RCTs) and meta-analyses that aggregate data from individual trials. These studies primarily explored how symptoms change over time when Tricard was studied alongside a patient’s existing treatment plan, often in comparison to a placebo group.

The research examined patient-reported outcomes describing perceived discomfort, specifically monitoring the number of chest pain episodes recorded each week. Studies also research examined patient usage of short-acting relief medication, such as the number of nitrates used. Findings describe patterns observed in the studies where patients reported how symptoms evolved in the observed populations, regarding both the frequency of their symptoms and the use of acute relief medication over the short study intervals, typically lasting a few weeks.

How Trials Measured Symptom and Functional Change

To gather objective data, researchers assessed outcomes reflecting daily functioning or activity level, primarily through exercise capacity endpoints. This involved measuring the time it took for the patient to develop anginal pain during a controlled stress test, as well as the total time they were able to exercise. Studies report how symptoms evolved in the observed populations based on these physical exertion tests. Findings were mixed regarding objective measures like total exercise time; however, the research describes patterns related to time until symptoms first appear.

What is Still Uncertain About the Research Evidence

Despite the existing research, there are recognized research limitation frames and evidence gaps. The key uncertainty lies in the absence of large-scale trials designed to measure whether patterns exist related to major clinical events, such as hospitalizations or survival, over many years of treatment for stable angina.

Furthermore, in the research area of heart failure, the sample sizes were modest in many of the supporting trials, and some methodological weaknesses have been documented by reviewers. This means that while studies contribute to understanding symptom patterns and physiological strain, the certainty remains low for drawing definitive conclusions about the long-term clinical relevance of the measured changes.

Key Studies & References European Medicines Agency (EMA) Product Information/Summary of Product Characteristics (Generic Reference)

Common questions about Tricard (FAQ)

---

Q: What is Tricard used for?

According to the official product information, Tricard is prescribed to manage chronic stable angina (chest pain) and to help reduce the risk of future cardiovascular events following an Acute Coronary Syndrome (ACS), such as a heart attack or unstable angina. It is indicated for use as part of a treatment plan for patients with these conditions.

---

Q: How does Tricard work in the body?

Regulatory documents state that Tricard is classified as an antiplatelet agent. It works by interfering with the process that causes platelets (blood components) to stick together and form clots in the arteries. This antiplatelet action is intended to maintain blood flow and reduce the risk of clot-related events in patients with certain heart conditions.

---

Q: Can Tricard be taken with or without food?

Official product information indicates that Tricard may be taken independent of meals, either with or without food. Its therapeutic effect is not dependent on simultaneous food intake. The official guidance states that taking it at a consistent time may aid adherence.

---

Q: Is Tricard safe to take long-term?

Studies and official information indicate that Tricard is designed for long-term use in eligible patients for the management of chronic conditions. Its safety and effectiveness have been evaluated over several years in clinical trials for its approved indications. Regulatory sources recommend regular follow-up with a healthcare provider during continued treatment.

---

Q: What should I do if I miss a dose of Tricard?

Official product information contains specific instructions regarding missed doses, which detail when a missed dose should be taken or skipped. This guidance is based on the time elapsed since the missed dose and the proximity to the next scheduled dose. Patients are advised to refer to the package leaflet or consult their prescriber for the official instructions on managing a missed dose.

---

Q: Does Tricard cause changes in blood pressure?

Regulatory documents clarify that Tricard is not a primary medication for lowering blood pressure. However, as it affects the circulatory system and is often part of a complex cardiovascular treatment regimen, changes in a patient's blood pressure may occur. Patients should consult their prescribing healthcare professional if they experience any concerning changes to their blood pressure.

Official Storage Requirements

Tricard (Trimetazidine Dihydrochloride) must be stored strictly in accordance with official labeling to maintain its stability and quality. The medicinal product must be stored in its original container and kept out of the sight and reach of children.

Storage Condition	Requirement
Maximum Temperature	Do not store above 30 C (controlled room temperature).
Protection	Must be protected from light and kept in its tightly closed original packaging.
Shelf-Life	Do not use the tablets after the expiry date printed on the carton.

---

Official Disposal Rules

Disposal of unused or expired Tricard must follow local regulatory requirements. The preferred method is to use an authorized drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt, coffee grounds) in a sealed bag before being placed in household trash. Do not flush the tablets down the toilet or pour them down the sink.